Kum 12-14 inkar vbc 2.5-te Covid vaccine pe tawh ; Kum 5-12 inkarte tan Corbevax pek rawt

India ramah naupang kum 12-14 inkar mi vaibelchhe 2.5-ten Covid-19 vaccine an la tawh a, dose kima la mi nuai 17 an awm tawh bawk. March 16 aṭang khan kum 12-14 inkarte hi vaccine pek ṭan an ni.

India drug regulator, Drug Controller General of India (DCGI)-a Subject Expert Committee (SEC) chuan kum 5-12 inkarte tan Biological E siam, Covid vaccine Corbevax hmang turin rawtna a thlen bawk a, union health ministry pawmpuina nghah mek a ni. Corbevax hi kum 12-14 inkarte hnenah pawh pek a ni.

Hyderabad-a hmunpui nei, vaccine siamtu Biologicial E siam, Corbevax hi India ram leilunga Receptor Binding Domain (RBD) Protein sub-unit vaccine siamchhuah hmasa ber a ni. Private market-ah chuan Corbevax dose khat Rs 990 niin, sorkar hospital leh facility-ah chuan Rs 145 a ni thung.

Kum 15-18 inkarte chu kumin January 3 aṭang khan vaccine hi pek ṭan ni bawkin, mi vaibelchhe 5.8 ten vaccine hi an la tawh a, an zinga vaibelchhe li chuangin dose kimin an la tawh a ni. Kum 15-18 inkarte hi Covaxin pek an ni.

India ram pumah Covid vaccine hi dose vaibelcheh 187 chuang pek chhuah a ni tawh a, heng zingah hian booster dose, precaution dose tia sawi bawk vaibelchhe 2.6 a tel.

Hri kai thar 2,451 awm belh
India ram pumah Ningani khan Covid-19 hri kai thar 2,451 an awm belh a, hemi ni vek hian hri vanga thi mi 54 an awm bawk.

Hun eng emaw chen hri kai mek, active case a tlahniam hnuah an pung leh ṭan a, nimin zing dar 8-a union health ministry-in data a tihchhuahah ram pumah hri kai mek awm zat hi 14,241 an tling leh tawh a ni. Active case hi hri kai hmuh chhuah tawh aṭangin 0.03% an ni.

Nitina hri kai thar, daily positivity rate pawh a sang leh hret a, 0.55% niin weekly positivity rate chu 0.47% ah a kai ve leh bawk. Hripui vanga thi hi mi 5,22,116 awm tawhin, thihpui hi 1.21% an ni.